

CONTACT - Media:

Amsterdam +31.20.550.4488
Lisbon +351.217.900.029
New York +1.212.656.2411

Brussels +32.2.509.1392
London +44.20.7379.2789
Paris +33.1.49.27.11.33

CONTACT - Investor Relations:

New York +1.212.656.5700

nyx.com

Please follow us at:
[Exchanges Blog](#)
[Facebook](#)
[LinkedIn](#)
[Twitter](#)

NYSE Euronext Announces Trading Volumes for July 2013

*Global Derivatives ADV Up Year-over-Year but Down Sequentially, Ex Bclear
European and U.S. Cash Equities ADV Down Year-over-Year and Sequentially*

August 7, 2013 – NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for July 2013¹. Global derivatives average daily volume (“ADV”) of 6.4 million contracts, excluding Bclear in July 2013 increased 3.2% compared to July 2012, but decreased 27.1% from June 2013. U.S. equity options volumes increased 2.1% compared to July 2012, but decreased 20.7% sequentially. ADV in U.S. cash equities and in European cash equities declined both year-over-year and month-over-month.

Highlights

- NYSE Euronext global derivatives ADV in June 2013 of 6.4 million contracts, excluding Bclear, increased 3.2% from July 2012, but decreased 27.1% from June 2013 levels.
- NYSE Euronext European derivatives products ADV in July 2013 of 2.8 million contracts, excluding Bclear, increased 5.4% compared to July 2012, but decreased 33.1% from June 2013 levels. Including Bclear, NYSE Liffe’s trade administration and clearing service for OTC products, European derivatives ADV decreased 2.7% compared to July 2012, and decreased 29.4% from June 2013.
- NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex Options) ADV of 3.6 million contracts in July 2013 increased 2.1% compared to July 2012 levels, but decreased 20.7% from June 2013 levels. NYSE Euronext’s U.S. options exchanges accounted for 26.6% of total U.S. consolidated equity options trading in July 2013, up from 25.9% in June 2012, but down from 27.5% in June 2013.
- NYSE Liffe U.S. ADV of approximately 35,000 contracts decreased from 53,400 contracts in July 2012 and decreased from 96,300 contracts in June 2013.
- NYSE Euronext European cash products ADV of 1.4 million transactions in July 2013 decreased 5.0% compared to July 2012 and decreased 8.3% compared to June 2013.
- NYSE Euronext U.S. cash products (NYSE, NYSE Arca and NYSE MKT) handled ADV of 1.4 billion shares in July 2013 decreased 15.8% compared to July 2012 and decreased 23.1% compared to June 2013. NYSE Euronext’s Tape A matched market share in July 2013 was 30.6%, down from 32.1% in July 2012 and down from 32.4% in June 2013.

¹ All NYSE Euronext derivatives transactions count buy and sell orders together as a single transaction. NYSE Euronext European equities transactions count each buy and sell order as separate transactions, NYSE Euronext U.S. equities transactions count buy and sell orders together as a single transaction.

Please [click here](#) for the Monthly Transaction Activity Data Table.

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: <http://www.nyx.com>.

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

This written communication contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "may," "hope," "will," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential," "continue," "could," "future" or the negative of those terms or other words of similar meaning. You should carefully read forward-looking statements, including statements that contain these words, because they discuss our future expectations or state other "forward-looking" information. Forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. ICE Group, ICE and NYSE Euronext caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement.

Forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving ICE Group, ICE and NYSE Euronext, including future financial results, ICE's and NYSE Euronext's plans, objectives, expectations and intentions, the expected timing of completion of the transaction and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in ICE's and NYSE Euronext's filings with the U.S. Securities and Exchange Commission (the "SEC"). These risks and uncertainties include, without limitation, the following: the inability to close the merger in a timely manner; the failure to satisfy other conditions to completion of the merger, including receipt of required regulatory and other approvals; the failure of the proposed transaction to close for any other reason; the possibility that any of the anticipated benefits of the proposed transaction will not be realized; the risk that integration of NYSE Euronext's operations with those of ICE will be materially delayed or will be more costly or difficult than expected; the challenges of integrating and retaining key employees; the effect of the announcement of the transaction on ICE's, NYSE Euronext's or the combined company's respective business relationships, operating results and business generally; the possibility that the anticipated synergies and cost savings of the merger will not be realized, or will not be realized within the expected time period; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; diversion of management's attention from ongoing business operations and opportunities; general competitive, economic, political and

market conditions and fluctuations; actions taken or conditions imposed by the United States and foreign governments or regulatory authorities; and adverse outcomes of pending or threatened litigation or government investigations. In addition, you should carefully consider the risks and uncertainties and other factors that may affect future results of the combined company, as are described in the section entitled “Risk Factors” in the joint proxy statement/prospectus filed by ICE Group with the SEC, and as described in ICE’s and NYSE Euronext’s respective filings with the SEC that are available on the SEC’s web site located at www.sec.gov, including the sections entitled “Risk Factors” in ICE’s Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 6, 2013, and “Risk Factors” in NYSE Euronext’s Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 26, 2013. You should not place undue reliance on forward-looking statements, which speak only as of the date of this written communication. Except for any obligations to disclose material information under the Federal securities laws, ICE Group, ICE and NYSE Euronext undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this written communication.

IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction, ICE Group has filed with the SEC a registration statement on Form S-4, which the SEC has declared effective and which contains a joint proxy statement/prospectus with respect to the proposed acquisition of NYSE Euronext by ICE Group. The final joint proxy statement/prospectus has been delivered to the stockholders of ICE and NYSE Euronext. INVESTORS AND SECURITY HOLDERS OF BOTH ICE AND NYSE EURONEXT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY, INCLUDING ANY DOCUMENTS PREVIOUSLY FILED WITH THE SEC AND INCORPORATED BY REFERENCE INTO THE JOINT PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE IT CONTAINS IMPORTANT INFORMATION REGARDING ICE, NYSE EURONEXT AND THE PROPOSED TRANSACTION. Investors and security holders may obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about ICE and NYSE Euronext, without charge, at the SEC’s website at <http://www.sec.gov>. Investors may also obtain these documents, without charge, from ICE’s website at <http://www.theice.com> and from NYSE Euronext’s website at <http://www.nyx.com>.

NYSE Euronext
Monthly Volume Summary

	Average Daily Volume			Total Volume			Average Daily Volume		Total Volume		
							% Chg vs.		% Chg vs.		
(Unaudited; contracts in thousands)	juil-13	juil-12	% Chg	juil-13	juil-12	% Chg	YTD 2013	YTD 2012	YTD 2013	YTD 2012	
Number of Trading Days - European Cash	23	22		23	22		148		148		
Number of Trading Days - European Derivatives	23	22		23	22		149		149		
Number of Trading Days - U.S. Markets	22	21		22	21		146		146		
European Derivatives Products	3 366	3 460	-2,7%	77 425	76 120	1,7%	4 137	5,9%	616 449	5,2%	
<i>of which Bclear</i>	585	822	-28,8%	13 464	18 085	-25,6%	779	-31,9%	116 130	-32,3%	
Total Fixed Income Products	2 117	1 802	17,5%	48 699	39 633	22,9%	2 529	36,4%	376 786	35,5%	
Short Term Interest Rate Products	1 988	1 678	18,5%	45 731	36 921	23,9%	2 350	37,8%	350 129	36,9%	
Medium and Long Term Interest Rate Products ¹	129	123	4,7%	2 968	2 712	9,4%	179	21,0%	26 657	20,2%	
Total Equity Products ²	1 153	1 540	-25,1%	26 515	33 878	-21,7%	1 517	-22,9%	226 049	-23,4%	
Individual Equity Products	751	1 115	-32,6%	17 284	24 539	-29,6%	1 002	-32,0%	149 265	-32,4%	
Futures	426	685	-37,9%	9 790	15 068	-35,0%	601	-39,6%	89 545	-40,0%	
Options	326	430	-24,3%	7 494	9 470	-20,9%	401	-16,1%	59 720	-16,7%	
Equity Index Products	401	425	-5,5%	9 230	9 340	-1,2%	515	4,2%	76 784	3,5%	
<i>of which Bclear</i>	585	822	-28,8%	13 454	18 085	-25,6%	778	-32,0%	115 979	-32,4%	
Individual Equity Products	512	776	-34,0%	11 785	17 075	-31,0%	674	-37,2%	100 418	-37,7%	
Futures	426	669	-36,4%	9 790	14 715	-33,5%	584	-39,8%	87 089	-40,2%	
Options	87	107	-19,2%	1 995	2 360	-15,5%	89	-12,9%	13 329	-13,5%	
Equity Index Products	73	46	58,0%	1 669	1 010	65,2%	104	48,6%	15 561	47,6%	
Commodity Products	96	119	-18,9%	2 211	2 609	-15,2%	91	6,8%	13 614	6,0%	
U.S. Derivatives Products											
Equity Options ³											
NYSE Euronext Options Contracts	3 562	3 487	2,1%	78 354	73 225	7,0%	4 194	6,3%	612 267	6,3%	
Total Consolidated Options Contracts	13 412	13 459	-0,4%	295 059	282 647	4,4%	15 138	0,2%	2 210 206	0,2%	
NYSE Group Share of Total	26,6%	25,9%		26,6%	25,9%		27,7%	1,6%	27,7%	1,6%	
NYSE Liffe U.S.											
Futures and Futures Options Volume*	35,0	53,4	-34,4%	805	1 121	-28,2%	57,1	-29,0%	8 557,6	-29,0%	
European Cash Products (trades in thousands)	1 390	1 463	-5,0%	31 961	32 180	-0,7%	1 419	-12,3%	209 981	-12,9%	
Equities	1 347	1 415	-4,8%	30 971	31 131	-0,5%	1 368	-12,6%	202 522	-13,2%	
Exchange-Traded Funds	13	13	-1,0%	296	286	3,5%	14	-1,3%	2 076	-1,9%	
Structured Products	26	29	-9,8%	601	637	-5,7%	31	-5,5%	4 631	-6,1%	
Bonds	4	6	-29,0%	93	126	-25,8%	5	0,4%	752	-0,2%	
U.S. Cash Products (shares in millions) ⁵	1 394	1 655	-15,8%	30 662	34 763	-11,8%	1 558	-12,6%	227 426	-12,6%	
NYSE Listed (Tape A) Issues ⁴											
Handled Volume ⁵	989	1 180	-16,2%	21 752	24 781	-12,2%	1 115	-12,4%	162 829	-12,4%	
Matched Volume ⁶	953	1 124	-15,2%	20 976	23 601	-11,1%	1 074	-11,0%	156 841	-11,0%	
Total NYSE Listed Consolidated Volume	3 117	3 503	-11,0%	68 574	73 566	-6,8%	3 525	-8,5%	514 596	-8,5%	
Share of Total Consolidated Volume											
Handled Volume ⁵	31,7%	33,7%	-2,0%	31,7%	33,7%	-2,0%	31,6%	-1,4%	31,6%	-1,4%	
Matched Volume ⁶	30,6%	32,1%	-1,5%	30,6%	32,1%	-1,5%	30,5%	-0,9%	30,5%	-0,9%	
NYSE Arca, MKT and Regional (Tape B) Listed Issues											
Handled Volume ⁵	230	233	-1,0%	5 068	4 885	3,7%	252	-5,3%	36 831	-5,3%	
Matched Volume ⁶	212	212	0,1%	4 669	4 454	4,8%	232	-2,9%	33 927	-2,9%	
Total NYSE Arca & MKT Listed Consolidated Volume	1 008	971	3,8%	22 170	20 395	8,7%	1 107	-1,9%	161 678	-1,9%	
Share of Total Consolidated Volume											
Handled Volume ⁵	22,9%	24,0%	-1,1%	22,9%	24,0%	-1,1%	22,8%	-0,8%	22,8%	-0,8%	
Matched Volume ⁶	21,1%	21,8%	-0,7%	21,1%	21,8%	-0,7%	21,0%	-0,2%	21,0%	-0,2%	
Nasdaq Listed (Tape C) Issues											
Handled Volume ⁵	175	243	-28,0%	3 842	5 097	-24,6%	190	-21,4%	27 765	-21,4%	
Matched Volume ⁶	156	210	-25,7%	3 438	4 415	-22,1%	170	-17,7%	24 806	-17,7%	
Total Nasdaq Listed Consolidated Volume	1 633	1 649	-1,0%	35 926	34 627	3,8%	1 775	-0,1%	259 221	-0,1%	
Share of Total Consolidated Volume											
Handled Volume ⁵	10,7%	14,7%	-4,0%	10,7%	14,7%	-4,0%	10,7%	-2,9%	10,7%	-2,9%	
Matched Volume ⁶	9,6%	12,7%	-3,1%	9,6%	12,7%	-3,1%	9,6%	-2,0%	9,6%	-2,0%	
Exchange-Traded Products ^{5,7}											
Handled Volume ⁵	215	214	0,8%	4 737	4 488	5,6%	237	-5,5%	34 565	-5,5%	
Matched Volume ⁶	199	195	2,1%	4 372	4 087	7,0%	218	-3,0%	31 827	-3,0%	
Total ETF Consolidated Volume	955	912	4,6%	21 005	19 161	9,6%	1 066	-2,7%	155 578	-2,7%	
Share of Total Consolidated Volume											
Handled Volume ⁵	22,6%	23,4%	-0,8%	22,6%	23,4%	-0,8%	22,2%	-0,7%	22,2%	-0,7%	
Matched Volume ⁶	20,8%	21,3%	-0,5%	20,8%	21,3%	-0,5%	20,5%	0,0%	20,5%	0,0%	

¹ Data includes currency products.

² Includes all trading activities for Bclear, NYSE Liffe's clearing service for wholesale derivatives.

³ Includes trading in U.S. equity options contracts, not equity-index options.

⁴ Includes all volume executed in NYSE Group crossing sessions.

⁵ Represents the total number of shares of equity securities and ETFs internally matched on the NYSE Group's exchanges or routed to and executed at an external market center. NYSE Arca routing includes odd-lots.

⁶ Represents the total number of shares of equity securities and ETFs executed on the NYSE Group's exchanges.

⁷ Data included in previously identified categories.

* ADVs calculated with the appropriate number of NYSE Liffe U.S. trading days.

Source: NYSE Euronext, Options Clearing Corporation and Consolidated Tape as reported for equity securities.

All trading activity is single-counted, except European cash trading which is double counted to include both buys and sells.